The Validant Group today announced a strategic repositioning of its five companies into one globally regulated brand: Eliquent Life Sciences.
Eliquint Life Sciences is a fusion of five global regulatory consulting firms: Validant, Greenleaf Health, DataRevive, Oriel Stat-A-Matrix, and IDEC. The capabilities shared by this unrivaled alliance enable them to provide integrated solutions to meet a wide range of regulatory challenges. Elign Life Sciences offers a comprehensive range of services to help pharmaceutical, biotechnology, and medical device companies navigate the complex regulatory environment.
Tim Dietlin, CEO of Elignat Life Sciences, said: "Eliquent Life Sciences is an unprecedented combination of regulatory leaders, industry experts and technical experts. Our combined capabilities provide the best path forward for life sciences innovators around the world. In conclusion, Eliquint sets a new standard for regulatory excellence. ”
Full service
The Eliquint team works cross-functionally to provide life sciences innovators around the world with the solutions they need to obtain and maintain product licenses. Guided by decades of regulatory and clinical experience, Eliquent's team of life sciences experts has the expertise to help clients navigate a variety of models and phases into key global markets.
The comprehensive achievements and qualifications of the Eliquent team enable them to provide an end-to-end full range of services in the following areas:
Regulatory Affairs Solutions.
From the earliest stages of development to regulatory submissions to post-approval support, Eliquent's strong technical skills combined with clinical expertise can guide companies through approval and beyond.
Pharmacovigilance and post-market surveillance solutions.
Eliquent's bespoke pharmacovigilance services include strategic guidance and tangible global support to enable businesses to operate with confidence.
Quality & Compliance Solutions.
Eliquent's highly specialized compliance experts provide tailor-made solutions to provide best-in-class strategic support, technical guidance, and project-based outcomes.
Remedial solutions.
Eliquent's team of esteemed professionals, along with a global network of ready-to-deploy experts, has earned unrivalled credibility and trust in engaging with regulators and guiding businesses through successful remediation.
Expert training. Eliquent's customizable training programs provide on-site and remote training services to equip executive teams and employees with the skills and tools to create practical problem-solving processes and stay up-to-date with regulations, compliance, and quality standards.
The strategic repositioning of Elign Life Sciences is supported by GHO Capital. GHO Capital is a specialist investor in the healthcare sector in Europe. GHO Capital has been working with Validant since December 2018, having acquired DataRevive, a firm that provides regulatory strategy and consulting services to global clients in 2019, IDEC, a leading regulatory consulting firm in Japan, in November 2020, and Oriel Stat A, a global consulting and training firm for the medical device industry, in December 2020 Matrix and acquired Greenleaf Health, a leading FDA regulatory consulting firm, in April 2021.
About GHO Capital
Global Healthcare Opportunities, also known as GHO Capital Partners LLP, is a leading specialist healthcare investment advisory firm headquartered in London. We apply our global capabilities and perspective to identify high-growth healthcare opportunities, building market-leading businesses with global strategic value with pan-European and transatlantic internationalization. Our proven track record of investing reflects our unrivalled industry expertise and network depth. We work with strong management teams to create long-term sustainable value and improve the efficiency of healthcare delivery, resulting in better, faster, and more accessible health care.